Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Int J Colorectal Dis. 2023 Aug 26;38(1):221. doi: 10.1007/s00384-023-04514-6.
Crohn's disease (CD) is a chronic inflammatory bowel disease that requires surgery in many cases. The aim of this article is to present the experience of a referral center regarding surgical interventions for CD, while also exploring the transformations that have occurred over 10 years.
The data of patients underwent abdominal surgery for CD between 2013 and 2022 were collected prospectively. Data were compared between two periods (2013-2017 and 2018-2022). Temporal trends were assessed with the Mann-Kendall trend test.
A total of 1059 individuals underwent 1176 surgical procedures, of which 67.1% were male. The median age of patients at the time of surgery was 36.0 years, and an overall increasing trend was observed in surgical volume (z = 3.04; p = 0.002). The proportion of patients treated with biologics increased from the first period (2013-2017) to the second (2018-2022), rising from 19.2% to 33.5% (p < 0.001). In the second stage, the proportion of patients who underwent surgery for abscesses or fistulas increased (47.8% vs. 40.0%, p = 0.028), while the percentage of emergency surgeries declined (3.0% vs. 7.1%, p = 0.001). Furthermore, there was a rise in the proportion of laparoscopic surgeries (76.5% vs. 63.7%, p < 0.001), coupled with a decrease in stoma rates (15.4% vs. 30.5%, p < 0.001) and postoperative complications (23.0% vs. 30.5%, p = 0.007).
The frequency of biologics use in CD surgery have increased over time, and the proportion of penetrating patients has grown. Minimally invasive surgical methods have become the norm, and surgical outcomes have markedly enhanced, evidenced by a substantial reduction in both stoma rates and complication rates.
克罗恩病(CD)是一种慢性炎症性肠病,在许多情况下需要手术。本文旨在介绍一家转诊中心在 CD 手术干预方面的经验,同时探讨 10 年来发生的变化。
前瞻性收集 2013 年至 2022 年间因 CD 行腹部手术的患者数据。将数据分为两个时期(2013-2017 年和 2018-2022 年)进行比较。采用曼肯德尔趋势检验评估时间趋势。
共有 1059 人接受了 1176 次手术,其中 67.1%为男性。手术时患者的中位年龄为 36.0 岁,手术量呈总体增加趋势(z=3.04;p=0.002)。接受生物制剂治疗的患者比例从第一阶段(2013-2017 年)增加到第二阶段(2018-2022 年),从 19.2%增加到 33.5%(p<0.001)。在第二阶段,因脓肿或瘘管而行手术的患者比例增加(47.8% vs. 40.0%,p=0.028),而急症手术的比例下降(3.0% vs. 7.1%,p=0.001)。此外,腹腔镜手术的比例上升(76.5% vs. 63.7%,p<0.001),造口率下降(15.4% vs. 30.5%,p<0.001),术后并发症发生率降低(23.0% vs. 30.5%,p=0.007)。
CD 手术中生物制剂的使用频率随时间增加,穿透性患者的比例增加。微创手术方法已成为常规,手术结果明显改善,造口率和并发症发生率均显著降低。